SLSara Luckenbill

Sara Luckenbill

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sara Luckenbill has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Policy mechanism matters: state-level pharmacist prescriptive authority and contraception prescribing

    by Julia Strasser, Sara Luckenbill, Risa Griffin, Jenna Bimbi, Tara Mancini, Qian Luo

    Introduction: State policies that authorize pharmacists to prescribe contraception could make contraceptive care more accessible in the US. Over half of states have implemented such a policy, either via: collaborative practice agreement (most restrictive), standing order, statewide protocol, or prescriptive authority (least restrictive). Methods: We used national prescription claims to measure variation in pharmacist-prescribed contraception by state policy type and by pharmacy affiliation in the thirty-one states that had a relevant policy in place as of 2024. Results: We identified a total of 3447 pharmacists, or 3.3% of all retail pharmacists in the US, prescribing contraception. Pharmacists prescribing contraception were most commonly affiliated with Walmart (17.4%), CVS (15.7%), Rite Aid (10.1%), and Safeway (9.4%). States with prescriptive authority or statewide protocols had significantly higher rates of pharmacist-prescribed contraception (11.6% and 5.9% of retail pharmacists, respectively), compared with states with standing orders (1.0%) or collaborative practice agreements (2.3%). Conclusion: This study found that the type of policy mechanism authorizing pharmacists to prescribe contraception plays a key role in determining uptake of this practice. State policies must be considered as part of a broader set of factors, including retail pharmacies' policies, pharmacist training, and reimbursement.

  • Open Access

    Few clinicians provide a wide range of contraceptive methods to Medicaid beneficiaries

    by Julia Strasser, Taylor Gorak, Sara Luckenbill, Yoon Hong Park, Qian Luo

    Introduction: Access to contraception services is an essential component of reproductive autonomy; however, low-income individuals frequently face barriers to care, including a shortage of providers who both accept Medicaid and offer contraception services. Methods: We used 2021 Transformed Medicaid Statistical Information System Prescription and Other Service files to identify clinicians who provided contraception (prescription, implant, and/or intrauterine device (IUD)) to Medicaid beneficiaries. Results: We identified 523 077 primary care and women's health specialty clinicians (obstetrician–gynecologists, family medicine, internal medicine, pediatrics, nurse practitioners, physician assistants, and midwives) who provided care to reproductive aged (15–44 years) female Medicaid beneficiaries for any service; of these, only 181 019 (34.6%) provided at least one contraception method to Medicaid beneficiaries and even fewer 20 160 (3.9%) provided prescriptions (pill, patch, and/or ring), IUDs, and implants. Over half (54%) of US counties had greater or equal numbers of advanced practice clinicians—nurse practitioners, physician assistants, and midwives—prescribing contraception compared with physicians. Conclusion: Few clinicians provided a wide range of contraception to Medicaid beneficiaries. Advanced practice clinicians are important providers in counties with limited access to physicians. Documenting workforce variation for contraception care has important implications for access, especially as recent policy changes may make contraception less accessible for Medicaid beneficiaries.

  • IRF7 controls spontaneous autoimmune germinal center and plasma cell checkpoints

    by Adam J. Fike, Kristen N. Bricker, Michael V. Gonzalez, Anju Maharjan, Tien Bui, Keomonyroth Nuon, Scott M. Emrich, Julia L. Weber, Sara A. Luckenbill, Nicholas M. Choi, et al.

    How IRF7 promotes autoimmune B cell responses and systemic autoimmunity is unclear. Analysis of spontaneous SLE-prone mice deficient in IRF7 uncovered the IRF7 role in regulating autoimmune germinal center (GC), plasma cell (PC), and autoantibody responses and disease. IRF7, however, was dispensable for foreign antigen–driven GC, PC, and antibody responses. Competitive bone marrow (BM) chimeras highlighted the importance of IRF7 in hematopoietic cells in spontaneous GC and PC differentiation. Single-cell RNAseq of SLE-prone B cells indicated IRF7-mediated B cell differentiation through GC and PC fates. Mechanistic studies revealed that IRF7 promoted B cell differentiation through GC and PC fates by regulating the transcriptome, translation, and metabolism of SLE-prone B cells. Mixed BM chimeras demonstrated a requirement for B cell–intrinsic IRF7 in IgG autoantibody production but not in the regulation of spontaneous GC and PC responses. Altogether, we delineate previously unknown B cell–intrinsic and –extrinsic mechanisms of IRF7-promoted spontaneous GC and PC responses, loss of tolerance, autoantibody production, and SLE development.


  • Adolescent and Young Adult Perspectives on Contraception Post-Dobbs: “The Next Closest Step to Having Control Over My Own Body”

    by Lauryn King, Julia Strasser, Sara Luckenbill, Ellen Schenk, Danielle Tsevat, Julie Maslowsky


  • Open Access

    Context-Dependent miR-21 Regulation of TLR7-Mediated Autoimmune and Foreign Antigen–Driven Antibody-Forming Cell and Germinal Center Responses

    by Stephanie L. Schell, Kristen N. Bricker, Adam J. Fike, Sathi Babu Chodisetti, Phillip P. Domeier, Nicholas M. Choi, Melinda J. Fasnacht, Sara A Luckenbill, Steven F. Ziegler, Ziaur S. M. Rahman

    MicroRNAs (miRNAs) are involved in healthy B cell responses and the loss of tolerance in systemic lupus erythematosus (SLE), although the role of many miRNAs remains poorly understood. Dampening miR-21 activity was previously shown to reduce splenomegaly and blood urea nitrogen levels in SLE-prone mice, but the detailed cellular responses and mechanism of action remains unexplored. In this study, using the TLR7 agonist, imiquimod-induced SLE model, we observed that loss of miR-21 in Sle1b mice prevented the formation of plasma cells and autoantibody-producing Ab-forming cells (AFCs) without a significant effect on the magnitude of the germinal center (GC) response. We further observed reduced dendritic cell and monocyte numbers in the spleens of miR-21–deficient Sle1b mice that were associated with reduced IFN, proinflammatory cytokines, and effector CD4+ T cell responses. RNA sequencing analysis on B cells from miR-21–deficient Sle1b mice revealed reduced activation and response to IFN, and cytokine and target array analysis revealed modulation of numerous miR-21 target genes in response to TLR7 activation and type I IFN stimulation. Our findings in the B6.Sle1b.Yaa (Sle1bYaa) spontaneous model recapitulated the miR-21 role in TLR7-induced responses with an additional role in autoimmune GC and T follicular helper responses. Finally, immunization with T-dependent Ag revealed a role for miR-21 in foreign Ag–driven GC and Ab, but not AFC, responses. Our data suggest a potential multifaceted, context-dependent role for miR-21 in autoimmune and foreign Ag–driven AFC and GC responses. Further study is warranted to delineate the cell-intrinsic requirements and mechanisms of miR-21 during infection and SLE development.


  • Open Access

    Context-dependent miR-21 regulation of TLR7-mediated autoimmune and foreign antigen driven antibody-forming cell and germinal center responses

    by Stephanie L. Schell, Kristen N. Bricker, Adam J. Fike, Sathi Babu Chodisetti, Phillip P. Domeier, Nicholas M. Choi, Melinda J. Fasnacht, Sara A. Luckenbill, Steven F. Ziegler, Ziaur S.M. Rahman

    MicroRNAs (miRNAs) are involved in healthy B cell responses and the loss of tolerance in systemic lupus erythematosus (SLE), though the role of many miRNAs remains poorly understood. Dampening miR-21 activity was previously shown to reduce splenomegaly and blood urea nitrogen levels in SLE-prone mice, but the detailed cellular responses and mechanism of action remains unexplored. Herein, using the TLR7 agonist imiquimod-induced SLE model, we observed that loss of miR-21 in Sle1b mice prevented the formation of plasma cells and autoantibody forming cells (AFC), without a significant effect on the magnitude of the germinal center (GC) response. We further observed reduced dendritic cell and monocyte numbers in the spleens of miR-21 deficient Sle1b ( Sle1b .miR-21KO) mice that were associated with reduced interferon, proinflammatory cytokines, and effector CD4 + T cell responses. RNAseq analysis on B cells from Sle1b .miR-21KO mice revealed reduced activation and response to interferon and cytokine and target array analysis revealed modulation of numerous miR-21 target genes in response to TLR7 activation and type I interferon stimulation. Our findings in the B6. Sle1b .Yaa spontaneous model recapitulated the miR-21 role in TLR7-induced responses with an additional role in autoimmune GC and Tfh responses. Finally, immunization with T-dependent antigen revealed a role for miR-21 in foreign antigen driven GC and Ab, but not AFC responses. Our data suggest a potential multifaceted, context-dependent role for miR-21 in autoimmune and foreign antigen driven AFC and GC responses. Further study is warranted to delineate the cell-intrinsic requirements and mechanisms of miR-21 during infection and SLE development. Key Points: miR-21 has context dependent effects on AFC and GC responses miR-21 promotes TLR7-driven autoimmunity with activation of multiple B cell pathways miR-21 is required for optimal B cell responses to T-dependent foreign antigen